Das Klinikum Wels-Grieskirchen ist als größtes Ordensspital Österreichs eine Institution der Kongregation der Barmherzigen Schwestern vom heiligen Kreuz und der Franziskanerinnen von Vöcklabruck.

During the past decade, Klinikum Wels-Grieskirchen GmbH conducted 65 clinical trials. In the 10-year time frame, 65 clinical trials started and 33 clinical trials were completed, i.e. on average, 50.8% percent of trials that started reached the finish line to date. In the past 5 years, 21 clinical trials started and 21 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Klinikum Wels-Grieskirchen GmbH" #1 sponsor was "Arbeitsgemeinschaft medikamentoese Tumortherapie" with 12 trials, followed by "Austrian Breast & Colorectal Cancer Study Group" with 10 trials sponsored, "Celgene" with 7 trials sponsored, "Boehringer Ingelheim" with 6 trials sponsored and "Hoffmann-La Roche" with 6 trials sponsored. Other sponsors include 74 different institutions and companies that sponsored additional 58 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Klinikum Wels-Grieskirchen GmbH" #1 collaborator was "Hoffmann-La Roche" with 6 trials as a collaborator, "AstraZeneca" with 5 trials as a collaborator, "Amgen" with 3 trials as a collaborator, "Breast International Group" with 3 trials as a collaborator and "Roche Pharma AG" with 3 trials as a collaborator. Other collaborators include 62 different institutions and companies that were collaborators in the rest 66 trials.

According to Clinical.Site data, the most researched conditions in "Klinikum Wels-Grieskirchen GmbH" are "Breast Cancer" (9 trials), "Acute Myeloid Leukemia" (5 trials), "Crohn's Disease" (5 trials), "Multiple Myeloma" (4 trials) and "Carcinoma, Non-Small-Cell Lung" (3 trials). Many other conditions were trialed in "Klinikum Wels-Grieskirchen GmbH" in a lesser frequency.

Most popular intervention types in "Klinikum Wels-Grieskirchen GmbH" are "Drug" (88 trials), "Other" (15 trials), "Biological" (11 trials), "Device" (11 trials) and "Procedure" (8 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (26 trials), "Carboplatin" (6 trials), "Cisplatin" (6 trials), "Gemcitabine" (5 trials) and "Nivolumab" (5 trials). Other intervention names were less common.

The vast majority of trials in "Klinikum Wels-Grieskirchen GmbH" are 107 trials for "All" genders and 13 trials for "Female" genders.

Currently, there are NaN active trials in "Klinikum Wels-Grieskirchen GmbH". undefined are not yet recruiting, 19 are recruiting, 20 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 62 completed trials in Klinikum Wels-Grieskirchen GmbH, undefined suspended trials, and 14 terminated clinical trials to date.

Out of the total trials that were conducted in Klinikum Wels-Grieskirchen GmbH, 4 "Phase 1" clinical trials were conducted, 29 "Phase 2" clinical trials and 59 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 14 trials that are defined as “Not Applicable".

Klinikum Wels-Grieskirchen GmbH has several departments that took part in Clinical trials: "Klinikum Wels-Grieskirchen Abteilung für Innere Medizin IV" - 12 trials